Constitutive activation of the RAS-RAF-MEK-ERK pathway plays a crucial role in the resistance to EGFR-targeting agents in KRAS/BRAF–mutant CRC cells [7]. The gene discussed is MAP2K7; the disease is colorectal carcinoma.